JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Search

Quidel Corp

Uždarymo kaina

26.9 -0.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.95

Max

27.22

Pagrindiniai rodikliai

By Trading Economics

Darbuotojai

6,600

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+47.33% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

300M

1.7B

Ankstesnė atidarymo kaina

26.94

Ankstesnė uždarymo kaina

26.9

Quidel Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-31 17:40; UTC

Įsigijimai, susijungimai, perėmimai

Orange to Buy Lorca's 50% Stake in MasOrange for $4.9 Billion

2025-10-31 23:09; UTC

Uždarbis

Review & Preview: October Surprise -- Barrons.com

2025-10-31 22:44; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

2025-10-31 21:25; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

2025-10-31 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

2025-10-31 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

2025-10-31 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

2025-10-31 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

2025-10-31 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

2025-10-31 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-31 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-31 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-10-31 20:46; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

2025-10-31 20:22; UTC

Uždarbis

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

2025-10-31 20:02; UTC

Uždarbis

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

2025-10-31 19:55; UTC

Rinkos pokalbiai

Crude Futures Fall for Third Straight Month -- Market Talk

2025-10-31 19:54; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

2025-10-31 19:54; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

2025-10-31 19:26; UTC

Rinkos pokalbiai

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

2025-10-31 18:30; UTC

Uždarbis

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

2025-10-31 18:23; UTC

Rinkos pokalbiai

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

2025-10-31 18:09; UTC

Uždarbis

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

2025-10-31 18:08; UTC

Uždarbis

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

2025-10-31 17:36; UTC

Rinkos pokalbiai

Grain Futures Shrug Off Stronger Dollar -- Market Talk

2025-10-31 17:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls, Natural Gas Rig Count Rises -- Market Talk

2025-10-31 17:16; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Acquisition Likely Completed in First Half Next Year

2025-10-31 17:15; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Agreement Set to Be Signed By Year-Out

2025-10-31 17:14; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Acquisition Will Strengthen Position in Spain

2025-10-31 17:13; UTC

Įsigijimai, susijungimai, perėmimai

Orange Will Be Sole Owner of Spain's MasOrange Following Acquisition of Lorca's Stake

2025-10-31 17:12; UTC

Įsigijimai, susijungimai, perėmimai

Orange Reaches Deal to Buy Lorca's 50% Stake in MasOrange for EUR4.25B

Akcijų palyginimas

Kainos pokytis

Quidel Corp Prognozė

Kainos tikslas

By TipRanks

47.33% į viršų

12 mėnesių prognozė

Vidutinis 39.5 USD  47.33%

Aukščiausias 62 USD

Žemiausias 26 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Quidel Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

4

Pirkti

3

Laikyti

1

Parduoti

Finansinės naujienos

$

Apie bendrovę Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat